30.04.2024 - Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereafter “Valerio Therapeutics” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage .
E-Mail
IMAGE: Timeline of some of the key events establishing anticipation as a genuine biological phenomenon and somatic expansion as contributing toward Huntington s disease pathology. view more
Credit: : Darren G. Monckton in The Contribution of Somatic Expansion of the CAG Repeat to Symptomatic Development in Huntington s Disease: A Historical Perspective, Journal of Huntington s Disease 10:1 (February 2021)..
Amsterdam, February 11, 2021 - Recent genetic data from patients with Huntington s disease (HD) show that DNA repair is an important factor that determines how early or late the disease occurs in individuals who carry the expanded CAG repeat in the
HTT gene that causes HD. The processes of DNA repair further expand the CAG repeats in